Have you missed any of our webinars? You can watch the recordings here! All webinars are free of charge.

See what webinars are coming up

Oncology Care: Leveraging the Medically Integrated Pharmacy Care Model to Achieve Greater Cost Savings

During this webinar the speakers will lead a discussion around the pain points in oncology care and the various innovations in the care model and provider types that are emerging to meet the needs of payers. The speakers will contrast existing known models and the medically integrated pharmacy care model provider option and the value each shares and where they differ. They will also cover what a typical patient journey looks like in a medically integrated pharmacy care oncology model.

Gury Doshi, MD, Medical Director, Oral Oncolytics,
Jim Schwartz, RPh, Executive Director, Pharmacy Operations

View the webcast

Specialty Pipeline Development in Key and Unique Therapeutic

During this webinar, Ryan J. Atkinson, PharmD, MaxorPlus will help us take a look into the near future of potential specialty drug releases, their potential impact, and what it means to patients, pharmacies, and payers. Ryan will examine the landscape of drug development in pharmacy now and compare it to a time not too long ago. You'll also hear detailed discussions on Alzheimer’s Disease, Nonalcoholic steatohepatitis (NASH), and Cystic Fibrosis.

Ryan J. Atkinson, PharmD, MBASenior Director of Specialty Pharmacy Strategy

View the webcast

Predictive Analytics - Identifying Tomorrow's Challenges Today

Imagine the ability to improve the clinical and economic health of customers and patients by proactively identifying at-risk patients and opportunities to more effectively manage costs. Karim Prasla, PharmD, of Magellan Rx Management helps us: • Discover ways to improve patient clinical and cost outcomes through predictive analytics • Learn how to plan for future drug costs and identify top conditions and drugs driving spend • Uncover opportunities to proactively identify patients who are non-adherent to chronic medications and specialty conditions

Karim Prasla, PharmD Vice President of Clinical Outcomes Advanced Analytics and Research

View the webcast

Biosimilars: Balancing Cost, Competition, Innovation, & Regulatory Impact

This webcast tackles the tough issues related to biosimilars and offer new perspectives on pricing barriers to biosimilar market entry, pricing dynamics of biosimilars/reference products, and lost savings opportunity due to slow uptake of biosimilars. Information on the long term savings opportunity of biosimilars and key differences with biologics, biosimilars, reference, generics, and interchangeable products will be presented. Results of the June 2018 Confidio led Physician Biosimilar Discussion Panel, offering Physician’s perspective to utilization barriers, will be presented. Looking forward, the future 2019 biosimilar pipeline and projected 2031 biosimilar maturing schedule will be evaluated with the biosimilar licensure criteria used to demonstrate highly similar, clinically meaningful efficacy, and equal biosimilar safety. As part of federal efforts to reduce drug cost and expedite approval and market launch, this session will evaluate biosimilar regulatory developments & the 2018 FDA Biosimilar Action Plan. Attendees will appreciate a robust overview of biosimilars related to price, market competition, innovation, and regulatory impact.

Sonja Quale, PharmD, Chief Clinical Officer & Vice President Informatics
Scott Vogel, Partner

View the webcast

Enhancing Clinical Solutions: Influencing Specialty Patient Behaviors Through Mobile Technology

Specialty medication adherence is a priority for both clinicians and payers alike due to abundant evidence demonstrating its value in improving clinical and financial health outcomes. The reasons for patient medication non-adherence encompasses a large continuum, and it is difficult to employ systematic solutions with a “one-size fits all” approach. Healthcare companies looking to improve the specialty patient experience and ensure optimal outcomes are all too familiar with the challenges of engagement, education, and adoption. Investments in tools and content designed to educate and support the member are increasing, but getting patients to engage with that content remains a challenge. According to the Pew Research Center for Internet and Technology, 92% of Americans own a cell phone and most of them keep their devices switched on and within easy reach. Mobile technology enables the specialty pharmacy to enhance its relationship with patients and influence their behaviors.

Nick Page, PharmD Chief Pharmacy Officer
Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP Director of Outcomes Research

View the webcast

The Importance of a Value-Based PBM

During this session, the speaker will discuss new and relevant insights that will help transform the management of pharmacy benefits, specifically why your PBM should be considering a value-based model.

Major topics of discussion include:
  • When the world evolves, the PBM system must evolve with it
  • Evidence-based clinical care is important for your members and your bottom line
  • Putting the pharmacist at the center of pharmacy benefit management guarantees lower costs and improved outcomes
  • PBMs can only succeed when all stakeholders succeed
Matthew Lee Vice President of Strategic Partnerships

View the webcast

Using AI and Big DNA Data to Advance Drug Development and Delivery

Artificial intelligence is rapidly advancing the capabilities and possibilities of whole genome sequencing. Through the use of this advanced technology, the pharmaceutical industry can deliver precise dosing on a scale and at a level of accuracy never before seen. AI can provide personalized predictions to determine likely physical and psychological effects of drug interaction in an individual body. While big data is increasing our access to questions, it is also creating new discoveries and new questions that have yet to be answered. One thing is for sure, AI, big data, and whole genome sequencing will impact the cost of drug development and delivery. This webcast explores these topics in depth.

Ian Jenkins CEO

View the webcast

Medication Safety Management Empowered by Genetics: Improving Patient Outcomes and Lowering Costs

An individual’s genetics impacts their specific response to medications, thus affecting safety and efficacy. A comprehensive Medication Therapy Management (MTM) with genetics program has been shown to improve medication adherence, appropriateness, and reduce adversity associated with chronic conditions. Specifically, results have shown a 29% reduction in hospitalizations, 18% in Rx spend, and 24% in “slips & falls.” In a state-run retiree population, the overall reduction in cost-to-plan spending was >19% and increased member satisfaction.

Dr. Jeff Shaman, of Coriell Life Sciences, shares perspectives into the strategic reduction of healthcare costs by educating and engaging employees in a Medication Therapy Management program that incorporates genetics.

Jeff Shaman, PhD Chief Science Officer

View the webcast

Do You Really Know the Cost of Opioid Prescriptions to Your Health Plan?

Chronic opioid prescribing can be responsible for 15% of the total annual medical cost.

Experience derived from the treatment and chart review of 2,500 patients, OPCM has documented patient responses to opioids at different levels of usage and stages of detoxification. Proprietary predictive analytics reviews de-identified patient Rx data to rank the risk of overdose or abuse in addition to Rx patterns that identify over-prescribing providers that may be the cause of additional medical encounters.

The speaker will discuss the unrecognized health plan costs of chronic opioids and how they have gone unrecognized.

Michael Vasquez CEO & Founder, Opioid Clinical Management, Inc

View the webcast

Findings from PBMI's 2019 Trends in Specialty Drug Benefits Report

This webinar will review key findings from the most recent Trends in Specialty Drug Benefits report.   Report and webinar sponsored by Walgreens and AllianceRx Walgreens Prime.

Jane Lutz Executive Director, PBMI
Sharon Frazee PhD, MPH, Vice President of Research & Education, PBMI

View the webcast

Findings from PBMI's 2018 Trends in Drug Benefit Design Report

This webinar will review key findings from the most recent Trends in Drug Benefit Design report.  Report and webinar sponsored by Takeda Pharmaceuticals U.S.A., Inc.

Jane Lutz Executive Director, PBMI
Shelly Carey Research Director, PBMI

View the webcast

340B Ecosystem Management: Creating an Integrated Framework for a Dynamic 340B Environment

This webinar will discuss trends in contract pharmacy and onsite pharmacy strategies, how those strategies evolve against an ever-changing market landscape, and how covered entities can create an integrated and seamless 340B management program as their needs and priorities evolve.

Topics include:
  • Growth in provider-based specialty pharmacy
  • Trends in 340B contract pharmacy
  • Important service and capability expectations of 340B Covered Entities
  • The evolution of 340B management strategies and partnership considerations

Ross Halsne, VP Market & Product Strategy, American Health Care powered by Maxor

View the webcast

Are You Paying Attention to Trends?

A survey of universities, large non-profit organizations, and governmental agencies was conducted to determine if pharmacy trends in the non-profit labor market differ from reported industry trends. With rising concerns of affordability plans are challenged to keep costs low. Plans are pursuing a wider array of approaches to reduce health care costs and risk.

Their focus includes:
  • Proactively managing pharmacy spend, especially related to specialty pharmacy costs and utilization
  • Selecting a pharmacy benefit manager based on their ability to reduce costs and demonstrate improved outcomes
  • Growing use of plan designs to increase out-of-pocket costs to discourage use of overused and high-cost drugs.

Angelo Monaco, Market Research Consultant
Nicole Hancy, PharmD, Vice President of Clinical Services, Citizens Rx
Bill Barre, Executive Vice President of Business Development, Citizens Rx

View the webcast

Finding a Solution to Lower Prescription Drug Costs

High prescription drug costs can negatively impact plan sponsors and their members who need them. The recent Trump administration prescription drug cost-reduction plan has heightened the focus on finding a solution to reduce costs. As a result, many plan sponsors are demanding greater accountability and transparency from their pharmacy benefit manager (PBM). So, what can you do to ensure your PBM is delivering the most transparent and affordable solutions? During this session we will dive into the issues and important questions you should be asking your PBM to ensure transparency, the best possible financial performance, and complete alignment with your objectives.

Arlene Edlin, General Manager, Sales, Navitus
Gary Hattendorf, Regional Sales Vice President, Navitus

View the webcast

Game On! Helping Patients Win Through Innovative Solutions

As humans, we all derive some emotional satisfaction from playing a game. It's the reason why Candy Crush Saga has 50 million active monthly users on Facebook. Playing a game gives us a reward, provides an opportunity to socialize, offers a distraction from the stresses of everyday life, and is just downright fun.

Games and healthcare are two words that don't always find themselves in the same sentence. Until now. Learn how Express Scripts is keeping patients engaged daily in their care through a fun, user-friendly mobile experience.

Kyle Amelung, PharmD, BCPS
Sr Manager, Health Technology
Express Scripts

View the webcast

A Solution to the Generic Drug Price Inflation: Compound Alternatives

Over the past two years, the pharmacy industry has seen an an unprecedented surge in generic pricing, which has led to an unexpected increase in cost for many key stakeholders in the pharmaceutical supply chain. Under high generic drug prices, patients face higher copays and even decline their medications due to increased out-of-pocket costs. Plan sponsors struggle with higher drug spend and pharmacies receive inadequate reimbursements. Meanwhile, prescribers and pharmacists are switching disgruntled patients to alternative drug therapies, while plan sponsors scurry around to save on costs. PBMs and plan sponsors are now seeking guidance from local compounding pharmacists in search of compound alternatives. These alternatives are for medications that are on short supply, no longer on the market, and whose prices have been excessively inflated. Products such as Daraprim, oral vancomycin, Zovirax, and colchicine, are just a few examples of such medications that contain a compounding alternative in today’s market place.

This webinar presents results from compound alternative programs using claims information.

Del Doherty, PharmD, PhD, MPH, Vice President of Managed Care, PersonalMed, LLC
Angela Van Dyke, MHA, CPhT, National Sales Manager, PersonalMed, LLC

View the webcast
* By registering for a webinar, you are authorizing PBMI to send you emails about future webinars.  You may unsubscribe at any time.